ArticlePloS one2025
Association of prior opium addiction with incident non-alcoholic fatty liver disease: A case-control study.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Association between opium consumption and sarcopenia in middle-aged and older adults: findings from the Fasa Adults Cohort Study (FACS).Scientific reports · 2026Article
- Comparative Analysis of Coagulation and Liver Parameters in Individuals with Alcohol and Substance Use Disorders and Healthy Controls.Diagnostics (Basel, Switzerland) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundNon-alcoholic fatty liver disease (NAFLD) is a prevalent chronic liver condition with no approved pharmacological treatments. Given opium's potential metabolic effects on lipid profiles, blood pressure, and glucose levels, factors known to influence NAFLD, we hypothesized that opium addiction might be inversely associated with NAFLD risk.
objectiveTo investigate the association between opium addiction during a six-year period (2016-2022) and the subsequent incidence and severity of NAFLD in 2022 among participants of the Fasa Adult Cohort Study (FACS).
methodsAdults aged 35-70 were selected from the FACS baseline dataset (2016) after excluding individuals with NAFLD (based on the Fatty Liver Index and regional cutoffs), obesity, cancer, chronic liver diseases, or regular alcohol use. Of 550 randomly selected participants invited for sonography in 2022, 396 attended; 170 were newly diagnosed with NAFLD. Cases and controls were matched 1:1 using SPSS based on age, sex, diabetes, and hyperlipidemia. Opium addiction was defined using DSM-5 criteria via structured interviews, while NAFLD diagnosis and grading were performed using blinded ultrasound assessment. Fisher's exact and Fisher-Freeman-Halton tests were used for analysis. A post hoc power analysis was also conducted.
resultsThe final analysis included 206 participants (103 cases, 103 controls). Opium addiction was observed in 31 NAFLD cases and 72 controls, a non-significant difference. However, the prevalence of opium addiction differed significantly across NAFLD severity grades. The post hoc statistical power was estimated at 60%.
conclusionAlthough not statistically significant, fewer opium addicts developed NAFLD than non-addicts. This inverse trend, along with significant variation across NAFLD grades, suggests a possible association that warrants further investigation. Larger studies are needed to explore this potential relationship. If confirmed, opioid-based therapies may offer dual benefits for managing chronic pain and metabolic risk in selected NAFLD populations.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.